mRNA-Based RSV Vaccine Effective For Older Adults, Study Finds

MedPage Today (12/13, Kahn) reports, “Moderna’s mRNA-based RSV vaccine was effective at preventing RSV-associated lower respiratory tract disease in adults ages 60 and older, according to results of the randomized ConquerRSV trial.” The findings were published in the New England Journal of Medicine. Healio (12/13, Stulpin) also covers the story.